carcinoma was confirmed in all spectrum. Mod cases by FISH. These Pathol. results demonstrated 2009;22(2):291-8. that secretory breast carcinomas have immunohistochemical and genetic features that distinguish them from other basal-like tumours of the breast. 3. Observational Rare Cancers A review of available 2016 study Australia: Just a cancer data Little More Time investigating the Rare Cancers disparities existing for Update Report. incidence, mortality 2016 and survival across the cancer spectrum. The study provided a definition for rare cancers, and the burden of disease that rare and less common cancers pose across all ages in Australia 4. Study of Sturm D, Witt H, A study demonstrating 16 Oct diagnostic Hovestadt V, et al: subgroups of 2012 accuracy Hotspot mutations glioblastomas (GBM) in H3F3A and IDH1 that can be identified define distinct by specific molecular epigenetic and markers (H3F3A and biological IDH1 mutations). subgroups of glioblastoma. Cancer Cell 2012 5. Health Sabatini LM, US Study by 2014 economics Mathews C, Ptak D, Association for study et al: Genomic Molecular Pathology Sequencing on cost and value Procedure analysis of specific Microcosting genomic sequencing Analysis and Health procedures (GSPs) Economic gathered from Analysis: A representative Report of the laboratories’ data. Association for Cost-impact models for Molecular three clinical scenarios Pathology. J of Mol were generated Diagn 18:319-328, lung cancer
carcinoma spectrum. Mod Pathol. 2009;22(2):291-8. was confirmed in all cases by FISH. These results demonstrated that secretory breast carcinomas have immunohistochemical and genetic features that distinguish them from other basal-like tumours of the breast. 3. Observational study Rare Cancers Australia: Just a Little More Time Rare Cancers Update Report. 2016 A review of available cancer data investigating the disparities existing for incidence, mortality and survival across the cancer spectrum. The study provided a definition for rare cancers, and the burden of disease that rare and less common cancers pose across all ages in Australia 2016 4. Study of diagnostic accuracy Sturm D, Witt H, Hovestadt V, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012 A study demonstrating subgroups of glioblastomas (GBM) that can be identified by specific molecular markers (H3F3A and IDH1 mutations). 16 Oct 2012 5. Health economics study Sabatini LM, Mathews C, Ptak D, et al: Genomic Sequencing Procedure Microcosting Analysis and Health Economic Analysis: A Report of the Association for Molecular Pathology. J of Mol Diagn 18:319-328, US Study by Association for Molecular Pathology on cost and value analysis of specific genomic sequencing procedures (GSPs) gathered from representative laboratories’ data. Cost-impact models for three clinical scenarios were generated lung cancer 2014